Clinical evaluation of short-term defibrotide treatment of patients with atherosclerosis obliterans of the lower limbs.
Haemostasis
; 16 Suppl 1: 55-8, 1986.
Article
em En
| MEDLINE
| ID: mdl-2423422
ABSTRACT
Ten patients with atherosclerosis obliterans of the lower limbs (Fontaine stage IV) were studied under basal conditions during and after short-term administration of defibrotide (800 mg/day intravenously from day 1 to 10 and then 400 mg/day intramuscularly from day 11 to 30). The clinical effectiveness of defibrotide was evaluated not only clinically (subjective and objective symptomatology) but also by Doppler velocimetry (Windsor's Index (WI] and primary antiplasmin activity. Seven patients (70%) showed improvement in subjective and objective symptomatology. There were increases in WI at the end of intravenous treatment in 6 patients (60%). In the remaining 40%, WI did not change from basal values. All patients showed normalization of primary antiplasmin activity versus basal values (55.62%, 17.75 SD) at the end of both intravenous and intramuscular treatment (101.37%, 15.71 SD and 102.5%, 13.86 SD, respectively). Therefore, we think that defibrotide may be useful for therapy of atherosclerosis obliterans of the lower limbs.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Polidesoxirribonucleotídeos
/
Arteriosclerose Obliterante
/
Fibrinolíticos
Limite:
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Haemostasis
Ano de publicação:
1986
Tipo de documento:
Article